Investor Presentaiton
Progress through Q2 2013
1. Partner coordination & resource mobilization
•
Secured commitments toward zinc/ORS scale-up from 15 organizations and counting.
NORAD: USD 9M grant to CHAI to start implementation in three states: Kano, Lagos, and Rivers.
Finalizing second USD14M grant to expand program implementation to 5 additional states
(tentative selection: Kaduna, Katsina, Niger, Bauchi, Cross-Rivers).
At least one additional major investment is being planned for 2014.
Joint workplan/activity mapping document and M&E Framework development initiated
2. Provider & consumer demand generation
•
Completed Market Activation Plan for producing a national marketing campaign.
Completed qualitative research on consumer and provider studies
RFP issued for activation and creative demand generation messaging
PCN finalized and began implementing childhood illness management in CME for PPMVS, CPs
3. Supplier engagement
•
Fidson, Emzor, Tyonex and CHI-four major pharmaceutical suppliers-have registered
zinc/ORS products
CHI launched zinc/ORS in Q1; Olpharm launched zinc in Q2; Emzor, Fidson to launch Q3
Engaged pharmaceutical companies on cost-reduction opportunities and co-packaging designs
4. Regulatory environment
NAFDAC confirmed zinc and ORS as OTC products; PCN added zinc to list of PPMV-approved
medications.
NAFDAC appointed a focal person to oversee the progress of zinc and ORS registration dossiers.
| 8View entire presentation